TransMedics Group, Inc. (TMDX) saw its stock price surge 6.07% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 financial results and a robust outlook for 2025.
The medical technology company reported better-than-expected earnings and revenue for the fourth quarter. Earnings per share came in at $0.19, beating analysts' estimates of $0.18 by a modest margin. Revenue rose 49.83% year-over-year to $121.62 million, surpassing the consensus estimate of $110.29 million by a significant margin.
TransMedics Group's strong performance was driven by robust demand for its products and services, as well as operational efficiency and profitability, highlighted by a gross margin of 59% and positive income from operations and net income. Adding to the positive sentiment, TransMedics Group provided an upbeat revenue outlook for 2025. The company expects full-year revenue to range between $530 million and $552 million, exceeding the consensus estimate of $521.62 million. This guidance reflects the company's confidence in its growth prospects and the continued adoption of its innovative solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.